Barinthus Noncontrolling Interest In Consolidated Entity from 2010 to 2025
| BRNS Stock | 1.04 0.03 2.97% |
Noncontrolling Interest In Consolidated Entity | First Reported 2010-12-31 | Previous Quarter 393.3 K | Current Value 349.6 K | Quarterly Volatility 23.8 K |
Check Barinthus Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Barinthus Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 M, Interest Expense of 23.9 K or Total Revenue of 876.2 K, as well as many indicators such as Price To Sales Ratio of 193, Dividend Yield of 0.0 or PTB Ratio of 0.54. Barinthus financial statements analysis is a perfect complement when working with Barinthus Biotherapeutics Valuation or Volatility modules.
Barinthus | Noncontrolling Interest In Consolidated Entity |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.